Budesonide

Triple inhaled therapy with twice-daily budesonide, at two doses, glycopyrrolate and formoterol reduced the rate of moderate or severe COPD exacerbations compared with two dual-combination therapies, according to data from the ETHOS trial.

This year’s CHEST Annual Meeting, held from Oct. 19 to 23 in New Orleans, highlighted important research and issues in pulmonary, critical care and sleep medicine.

NEW ORLEANS — A subgroup analysis of the KRONOS study showed the reduction in COPD exacerbations observed with the triple fixed-dose combination budesonide/glycopyrrolate/formoterol fumarate metered-dose inhaler, as compared with a dual bronchodilator, was not driven by patients with a history of prior exacerbations.

The FDA has issued a complete response letter regarding the new drug application for PT010 — an inhaled triple-combination therapy — for COPD, according to a press release from the manufacturer.

Healio Pulmonology has you covered. The Editors have compiled a list of the most-popular articles posted on Healio Pulmonology in August.

New data from the ETHOS trial showed that triple-combination therapy with budesonide, glycopyrronium and formoterol at two different budesonide doses reduced exacerbations in patients with moderate to very severe COPD, according to a manufacturer press release.

Data from the PRACTICAL study showed that budesonide-formoterol reliever therapy in a single inhaler for patients with mild to moderate asthma was associated with a 31% reduction in the risk for severe exacerbations, as compared with maintenance budesonide plus terbutaline reliever therapy.

In this video, Ali Poyan Mehr, MD, regional director of the Glomerular Disease Program at Kaiser Permanente Northern California, discusses some of the major shifts in IgA nephropathy treatment and study in recent years.